ICH S7A Safety Pharmacology Studies for Human Pharmaceuticals

E1538042 UNEXPLORED

ICH S7A Safety Pharmacology Studies for Human Pharmaceuticals is an international guideline that outlines the core nonclinical safety pharmacology studies needed to evaluate the potential undesirable effects of new drugs on vital physiological functions before human use.

Try in SPARQL Jump to: Surface forms Disambiguation Referenced by

All labels observed (1)

Label	Occurrences
ICH S7A Safety Pharmacology Studies for Human Pharmaceuticals canonical	1

How this entity was disambiguated

This entity first appeared as the object of triple T22458035 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.

NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07

Target entity: ICH S7A Safety Pharmacology Studies for Human Pharmaceuticals
Context triple: [ICH M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals, relatedTo, ICH S7A Safety Pharmacology Studies for Human Pharmaceuticals]

A. ICH M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals
ICH M3(R2) is an international guideline that harmonizes requirements for nonclinical safety studies needed to support the initiation and progression of human clinical trials and the marketing authorization of pharmaceuticals.
B. ICH S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals
ICH S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals is an international guideline that outlines the nonclinical safety testing requirements for biotechnological products such as therapeutic proteins and monoclonal antibodies to support their clinical development and marketing authorization.
C. ICH S9 Nonclinical Evaluation for Anticancer Pharmaceuticals
ICH S9 Nonclinical Evaluation for Anticancer Pharmaceuticals is an international regulatory guideline that outlines the nonclinical safety studies needed to support the development and approval of anticancer drugs in humans.
D. ICH Q1 Stability Testing of New Drug Substances and Products
ICH Q1 Stability Testing of New Drug Substances and Products is an international regulatory guideline that defines the scientific principles and study requirements for assessing the stability, shelf life, and storage conditions of new pharmaceutical substances and finished products.
E. Certificates of Suitability to the monographs of the European Pharmacopoeia
Certificates of Suitability to the monographs of the European Pharmacopoeia are official documents issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM) confirming that a substance’s quality complies with the relevant European Pharmacopoeia monograph, thereby simplifying regulatory approval for medicines across Europe.
F. None of above. chosen
G. Unsure - the case is ambiguous/there is not enough information to decide.

NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07

Target entity: ICH S7A Safety Pharmacology Studies for Human Pharmaceuticals
Target entity description: ICH S7A Safety Pharmacology Studies for Human Pharmaceuticals is an international guideline that outlines the core nonclinical safety pharmacology studies needed to evaluate the potential undesirable effects of new drugs on vital physiological functions before human use.

A. ICH M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals
ICH M3(R2) is an international guideline that harmonizes requirements for nonclinical safety studies needed to support the initiation and progression of human clinical trials and the marketing authorization of pharmaceuticals.
B. ICH S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals
ICH S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals is an international guideline that outlines the nonclinical safety testing requirements for biotechnological products such as therapeutic proteins and monoclonal antibodies to support their clinical development and marketing authorization.
C. ICH S9 Nonclinical Evaluation for Anticancer Pharmaceuticals
ICH S9 Nonclinical Evaluation for Anticancer Pharmaceuticals is an international regulatory guideline that outlines the nonclinical safety studies needed to support the development and approval of anticancer drugs in humans.
D. ICH Q1 Stability Testing of New Drug Substances and Products
ICH Q1 Stability Testing of New Drug Substances and Products is an international regulatory guideline that defines the scientific principles and study requirements for assessing the stability, shelf life, and storage conditions of new pharmaceutical substances and finished products.
E. Certificates of Suitability to the monographs of the European Pharmacopoeia
Certificates of Suitability to the monographs of the European Pharmacopoeia are official documents issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM) confirming that a substance’s quality complies with the relevant European Pharmacopoeia monograph, thereby simplifying regulatory approval for medicines across Europe.
F. None of above. chosen

Referenced by (1)

Full triples — surface form annotated when it differs from this entity's canonical label.

ICH M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals → relatedTo → ICH S7A Safety Pharmacology Studies for Human Pharmaceuticals ⓘ

All labels observed (1)

How this entity was disambiguated Show

Referenced by (1)

How this entity was disambiguated